Overall, 335 (20.1%) participants carried germline P/LP variants, including 223 (13.4%) in high-penetrant BC genes [BRCA1 97 (5.8%), BRCA2 72 (4.3%), TP53 37 (2.2%), PALB2 18 (1.1%), CDH1 1 (0.1%), NF1 1 (0.1%), PTEN 1 (0.1%)] and 69 (4.1%) in moderate-penetrant BC genes [ATM 31 (1.9%), CHEK2 22 (1.3%), RAD51C 7 (0.4%), BRIP1 5 (0.3%), BARD1 1 (0.1%), RAD51D 1 (0.1%)]. This evidence concerns the gene PALB2 and breast cancer.